menu
    • menu
    [{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Clotrimazole","moa":"Cytochrome P450 51","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DF277","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DF289","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Salvat","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"G238","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Laboratorios Salvat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Salvat \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Salvat \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Laboratorios Salvat

    Menu

    Laboratorios Salvat

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery i...

                            Details : Clobetasol Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With...

                            Details : Clobetasol Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            January 30, 2020

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With...

                            Details : Clobetasol Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            January 29, 2020

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clotrimazole

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SVT-15652 Otic Solution for the Treatment of Otomycosis.

                            Details : SVT-15652 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otomycosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2018

                            Lead Product(s) : Clotrimazole

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa

                            Details : DF289 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otitis Externa.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 23, 2017

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF277

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema

                            Details : DF277 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otic Eczema.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 27, 2013

                            Lead Product(s) : DF277

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : G238

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatme...

                            Details : G238 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otomycosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 25, 2013

                            Lead Product(s) : G238

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric P...

                            Details : DF289 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otitis Media.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 28, 2011

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Laboratorios Salvat

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle ...

                            Details : DF289 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otitis Media.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 18, 2011

                            Lead Product(s) : DF289

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth